Sutro Biopharma, Inc.: Form 10-Q for the period ended Sep 30, 2019
Filed with the SEC on Nov 8, 2019 and accepted by EDGAR at Nov 7, 2019, 17:59 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2019-07-01 to 2019-09-30 | $12.3m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2019-01-01 to 2019-09-30 | $31.4m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 3 months2019-07-01 to 2019-09-30 | $16.9m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2019-01-01 to 2019-09-30 | $48.2m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2019-07-01 to 2019-09-30 | −$12.7m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2019-01-01 to 2019-09-30 | −$40.7m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2019-07-01 to 2019-09-30 | −$12.9m | us-gaap:NetIncomeLoss |
| Net income | 9 months2019-01-01 to 2019-09-30 | −$41.0m | us-gaap:NetIncomeLoss |
| Operating cash flow | 9 months2019-01-01 to 2019-09-30 | −$51.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2019-01-01 to 2019-09-30 | $1.4m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2019-09-30 | $12.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2019-09-30 | $135.6m | us-gaap:AssetsCurrent |
| Total assets | At period end2019-09-30 | $171.7m | us-gaap:Assets |
| Current liabilities | At period end2019-09-30 | $35.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2019-09-30 | $61.8m | us-gaap:Liabilities |
| Long-term debt | At period end2019-09-30 | $5.5m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2019-09-30 | $5.8m | us-gaap:DebtCurrent |
| Shareholders' equity | At period end2019-09-30 | $109.9m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001564590-19-041909. Last ingested by Listed: Oct 24, 2026, 15:12 ET. Listed shows no prices and gives no investment advice.